In IAP antagonist-sensitive cancer cells, depletion of cIAP1 following IAP antagonist treatment resulted in the formation of a RIPK1:caspase-8 complex with subsequent activation of caspase-8.16,32,38 To address the fraction of cIAP1 that remained following monovalent IAP antagonist treatment, we first considered the induction of the RIPK1:caspase-8 complex by monovalent or bivalent IAP antagonist treatment in EVSA-T cells, an IAP antagonist-sensitive breast cancer cell line. This evidence concerns the gene BIRC2 and breast cancer.